Author:
Booth Thomas C.,Thompson Gerard,Bulbeck Helen,Boele Florien,Buckley Craig,Cardoso Jorge,Dos Santos Canas Liane,Jenkinson David,Ashkan Keyoumars,Kreindler Jack,Huskens Nicky,Luis Aysha,McBain Catherine,Mills Samantha J.,Modat Marc,Morley Nick,Murphy Caroline,Ourselin Sebastian,Pennington Mark,Powell James,Summers David,Waldman Adam D.,Watts Colin,Williams Matthew,Grant Robin,Jenkinson Michael D.
Abstract
Objectiv eTo summarise current evidence for the utility of interval imaging in monitoring disease in adult brain tumours, and to develop a position for future evidence gathering while incorporating the application of data science and health economics.MethodsExperts in ‘interval imaging’ (imaging at pre-planned time-points to assess tumour status); data science; health economics, trial management of adult brain tumours, and patient representatives convened in London, UK. The current evidence on the use of interval imaging for monitoring brain tumours was reviewed. To improve the evidence that interval imaging has a role in disease management, we discussed specific themes of data science, health economics, statistical considerations, patient and carer perspectives, and multi-centre study design. Suggestions for future studies aimed at filling knowledge gaps were discussed.ResultsMeningioma and glioma were identified as priorities for interval imaging utility analysis. The “monitoring biomarkers” most commonly used in adult brain tumour patients were standard structural MRI features. Interval imaging was commonly scheduled to provide reported imaging prior to planned, regular clinic visits. There is limited evidence relating interval imaging in the absence of clinical deterioration to management change that alters morbidity, mortality, quality of life, or resource use. Progression-free survival is confounded as an outcome measure when using structural MRI in glioma. Uncertainty from imaging causes distress for some patients and their caregivers, while for others it provides an important indicator of disease activity. Any study design that changes imaging regimens should consider the potential for influencing current or planned therapeutic trials, ensure that opportunity costs are measured, and capture indirect benefits and added value.ConclusionEvidence for the value, and therefore utility, of regular interval imaging is currently lacking. Ongoing collaborative efforts will improve trial design and generate the evidence to optimise monitoring imaging biomarkers in standard of care brain tumour management.
Reference99 articles.
1. Updates in the management of brain metastases;Anvold;Neuro Oncol,2016
2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005
3. HowickJ
ChalmerI
GlasziouP
GreenhalghT
HeneghanC
LiberatiA
OxfordOxford Centre for Evidence-Based Medicine The Oxford 2011 levels of evidence2016
4. Guideline NG99.
5. Interval brain imaging for adults with cerebral glioma;Thompson;Cochrane Database System Rev,2019
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献